Parkman Healthcare Partners LLC Buys Shares of 594,202 Immunome, Inc. $IMNM

Parkman Healthcare Partners LLC bought a new position in Immunome, Inc. (NASDAQ:IMNM) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 594,202 shares of the company’s stock, valued at approximately $12,591,000.

Several other hedge funds have also added to or reduced their stakes in IMNM. Allworth Financial LP bought a new position in Immunome during the second quarter worth about $25,000. KBC Group NV bought a new stake in shares of Immunome in the first quarter worth about $60,000. BNP Paribas Financial Markets increased its holdings in shares of Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after acquiring an additional 2,909 shares in the last quarter. Strs Ohio acquired a new stake in shares of Immunome during the fourth quarter worth about $64,000. Finally, Tower Research Capital LLC TRC raised its position in shares of Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Activity

In related news, insider Kinney Horn sold 90,616 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a total value of $2,273,555.44. Following the completion of the transaction, the insider directly owned 50,366 shares of the company’s stock, valued at approximately $1,263,682.94. This trade represents a 64.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Isaac Barchas sold 11,048 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00. Following the transaction, the director owned 92,211 shares in the company, valued at $2,512,749.75. This represents a 10.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 682,310 shares of company stock valued at $15,675,566. 7.21% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on IMNM shares. Wedbush lifted their price objective on Immunome from $31.00 to $35.00 and gave the company an “outperform” rating in a report on Wednesday, August 12th. Barclays began coverage on shares of Immunome in a report on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price on the stock. Citigroup reaffirmed a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. HC Wainwright reiterated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Finally, Truist Financial increased their price objective on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.64.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $28.01 on Tuesday. The stock has a 50 day moving average price of $23.39 and a 200 day moving average price of $22.33. Immunome, Inc. has a 52 week low of $8.66 and a 52 week high of $30.06. The stock has a market capitalization of $3.18 billion, a PE ratio of -11.07 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.14). As a group, research analysts forecast that Immunome, Inc. will post -2.38 EPS for the current year.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.